Age-related decline in immunity: implications for vaccine responsiveness

References

• Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology120(4), 435–446 (2007).
   PubMed Web of Science ®Google Scholar
• Pawelec G. Immunity and ageing in man. Exp. Gerontol.41(12), 1239–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien. Med. Wochenschr.156(5–6), 130–141 (2006).
   PubMedGoogle Scholar
• Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert. Rev. Mol. Med.9(3), 1–17 (2007).
   PubMedGoogle Scholar
• Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J. Pathol.211(2), 144–156 (2007).
   PubMed Web of Science ®Google Scholar
• Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell3(4), 161–167 (2004).
   PubMed Web of Science ®Google Scholar
• Burns EA. Effects of aging on immune function. J. Nutr. Health Aging8(1), 9–18 (2004).
   PubMedGoogle Scholar
• Kondo M, Wagers AJ, Manz MG et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol.21, 759–806 (2003).
   PubMed Web of Science ®Google Scholar
• Kamminga LM, de Haan G. Cellular memory and hematopoietic stem cell aging. Stem Cells24(5), 1143–1149 (2006).
   PubMedGoogle Scholar
• Henckaerts E, Langer JC, Snoeck HW. Quantitative genetic variation in the hematopoietic stem cell and progenitor cell compartment and in lifespan are closely linked at multiple loci in BXD recombinant inbred mice. Blood104(2), 374–379 (2004).
   PubMedGoogle Scholar
• Yuan R, Astle CM, Chen J, Harrison DE. Genetic regulation of hematopoietic stem cell exhaustion during development and growth. Exp. Hematol.33(2), 243–250 (2005).
   PubMedGoogle Scholar
• Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature411(6835), 366–374 (2001).
   PubMed Web of Science ®Google Scholar
• Aspinall R, Andrew D. Thymic involution in aging. J. Clin. Immunol.20(4), 250–256 (2000).
   PubMed Web of Science ®Google Scholar
• Prelog M. Aging of the immune system: a risk factor for autoimmunity? Autoimmun. Rev.5(2), 136–139 (2006).
   PubMed Web of Science ®Google Scholar
• Varas A, Sacedon R, Hernandez-Lopez C et al. Age-dependent changes in thymic macrophages and dendritic cells. Microsc. Res. Tech.62(6), 501–507 (2003).
   PubMedGoogle Scholar
• Aspinall R. T cell development, ageing and interleukin-7. Mech. Ageing Dev.127(6), 572–578 (2006).
   PubMed Web of Science ®Google Scholar
• Andrew D, Aspinall R. Age-associated thymic atrophy is linked to a decline in IL-7 production. Exp. Gerontol.37(2–3), 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De MM, D’Ostilio A et al. Immunological changes in the elderly. Aging (Milano)11(5), 281–286 (1999).
   PubMedGoogle Scholar
• Schindowski K, Frohlich L, Maurer K, Muller WE, Eckert A. Age-related impairment of human T lymphocytes’ activation: specific differences between CD4+ and CD8+ subsets. Mech. Ageing Dev.123(4), 375–390 (2002).
   PubMed Web of Science ®Google Scholar
• Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat. Immunol.5(2), 133–139 (2004).
   PubMed Web of Science ®Google Scholar
• Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr. Opin. Immunol.16(2), 151–156 (2004).
   PubMed Web of Science ®Google Scholar
• Romanyukha AA, Yashin AI. Age related changes in population of peripheral T cells: towards a model of immunosenescence. Mech. Ageing Dev.124(4), 433–443 (2003).
   PubMedGoogle Scholar
• Davenport RJ. Immunity challenge. Sci. Aging Knowledge Environ.2003(23), OA1 (2003).
   PubMedGoogle Scholar
• Effros RB. Replicative senescence of CD8 T cells: effect on human ageing. Exp. Gerontol.39(4), 517–524 (2004).
   PubMed Web of Science ®Google Scholar
• Effros RB, Dagarag M, Valenzuela HF. in vitro senescence of immune cells. Exp. Gerontol.38(11–12), 1243–1249 (2003).
   PubMedGoogle Scholar
• Goronzy JJ, Fulbright JW, Crowson CS et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol.75(24), 12182–12187 (2001).
   PubMed Web of Science ®Google Scholar
• Pourgheysari B, Khan N, Best D et al. The CMV-specific CD4+ T cell response expands with age and markedly alters the CD4+ T cell repertoire. J. Virol.81(14), 7759–7765 (2007).
   PubMed Web of Science ®Google Scholar
• Trzonkowski P, Mysliwska J, Szmit E et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination – an impact of immunosenescence. Vaccine21(25–26), 3826–3836 (2003).
   PubMed Web of Science ®Google Scholar
• Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech. Ageing Dev.102(2–3), 199–209 (1998).
   PubMed Web of Science ®Google Scholar
• Fischer MB, Hauber I, Eggenbauer H et al. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood84(12), 4234–4241 (1994).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De MM, D’Ostilio A et al. The immune system in the elderly: II. Specific cellular immunity. Immunol. Res.20(2), 109–115 (1999).
   PubMed Web of Science ®Google Scholar
• Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo.J. Immunol.172(9), 5194–5199 (2004).
   PubMed Web of Science ®Google Scholar
• Toda A, Piccirillo CA. Development and function of naturally occurring CD4+CD25+ regulatory T cells. J. Leukoc. Biol.80(3), 458–470 (2006).
   PubMedGoogle Scholar
• Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol. Rev.212, 272–286 (2006).
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat. Immunol.6(4), 353–360 (2005).
   PubMed Web of Science ®Google Scholar
• Chatila TA. Role of regulatory T cells in human diseases. J. Allergy Clin. Immunol.116(5), 949–959 (2005).
   PubMed Web of Science ®Google Scholar
• Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J. Immunol.176(11), 6586–6593 (2006).
   PubMed Web of Science ®Google Scholar
• Tsaknaridis L, Spencer L, Culbertson N et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J. Neurosci. Res.74(2), 296–308 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson KM, Owen K, Witte PL. Aging and developmental transitions in the B cell lineage. Int. Immunol.14(11), 1313–1323 (2002).
   PubMed Web of Science ®Google Scholar
• Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on the common lymphoid progenitor to pro-B cell transition. J. Immunol.176(2), 1007–1012 (2006).
   PubMedGoogle Scholar
• Tsuboi I, Morimoto K, Hirabayashi Y et al. Senescent B lymphopoiesis is balanced in suppressive homeostasis: decrease in interleukin-7 and transforming growth factor-β levels in stromal cells of senescence-accelerated mice. Exp. Biol. Med. (Maywood)229(6), 494–502 (2004).
   PubMed Web of Science ®Google Scholar
• Stephan RP, Lill-Elghanian DA, Witte PL. Development of B cells in aged mice: decline in the ability of pro-B cells to respond to IL-7 but not to other growth factors. J. Immunol.158(4), 1598–1609 (1997).
   PubMedGoogle Scholar
• Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol.24(6), 343–349 (2003).
   PubMed Web of Science ®Google Scholar
• Souvannavong V, Lemaire C, Andreau K, Brown S, Adam A. Age-associated modulation of apoptosis and activation in murine B lymphocytes. Mech. Ageing Dev.103(3), 285–299 (1998).
   PubMedGoogle Scholar
• Zharhary D, Segev Y, Gershon H. The affinity and spectrum of cross reactivity of antibody production in senescent mice: the IgM response. Mech. Ageing Dev.6(5), 385–392 (1977).
   PubMedGoogle Scholar
• Johnson SA, Cambier JC. Ageing, autoimmunity and arthritis: senescence of the B cell compartment – implications for humoral immunity. Arthritis Res. Ther.6(4), 131–139 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng B, Han S, Takahashi Y, Kelsoe G. Immunosenescence and germinal center reaction. Immunol. Rev.160, 63–77 (1997).
   PubMed Web of Science ®Google Scholar
• Han S, Zheng B, Takahashi Y, Kelsoe G. Distinctive characteristics of germinal center B cells. Semin. Immunol.9(4), 255–260 (1997).
   PubMedGoogle Scholar
• Yang X, Stedra J, Cerny J. Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. J. Exp. Med.183(3), 959–970 (1996).
   PubMed Web of Science ®Google Scholar
• Lazuardi L, Jenewein B, Wolf AM et al. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology114(1), 37–43 (2005).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De MM, D’Ostilio A et al. The immune system in the elderly: III. Innate immunity. Immunol. Res.20(2), 117–126 (1999).
   PubMedGoogle Scholar
• Stout RD, Suttles J. Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes. Immunol. Rev.205, 60–71 (2005).
   PubMedGoogle Scholar
• Andrade CF, Waddell TK, Keshavjee S, Liu M. Innate immunity and organ transplantation: the potential role of Toll-like receptors. Am. J. Transplant.5(5), 969–975 (2005).
   PubMedGoogle Scholar
• Renshaw M, Rockwell J, Engleman C et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol.169(9), 4697–4701 (2002).
   PubMed Web of Science ®Google Scholar
• Garg M, Luo W, Kaplan AM, Bondada S. Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice. Infect. Immun.64(11), 4456–4462 (1996).
   PubMedGoogle Scholar
• Zissel G, Schlaak M, Muller-Quernheim J. Age-related decrease in accessory cell function of human alveolar macrophages. J. Investig. Med.47(1), 51–56 (1999).
   PubMed Web of Science ®Google Scholar
• Herrero C, Sebastian C, Marques L et al. Immunosenescence of macrophages: reduced MHC class II gene expression. Exp. Gerontol.37(2–3), 389–394 (2002).
   PubMed Web of Science ®Google Scholar
• de la Fuente M, Hernanz A, Guayerbas N, Alvarez P, Alvarado C. Changes with age in peritoneal macrophage functions. Implication of leukocytes in the oxidative stress of senescence. Cell Mol. Biol. (Noisy-le-grand)50, OL683–OL690 (2004).
   PubMedGoogle Scholar
• Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol.161(6), 2804–2809 (1998).
   PubMed Web of Science ®Google Scholar
• Wick G, Grubeck-Loebenstein B. Primary and secondary alterations of immune reactivity in the elderly: impact of dietary factors and disease. Immunol. Rev.160, 171–184 (1997).
   PubMedGoogle Scholar
• Sato H, Dobashi M. The distribution, immune complex trapping ability and morphology of follicular dendritic cells in popliteal lymph nodes of aged rats. Histol. Histopathol.13(1), 99–108 (1998).
   PubMedGoogle Scholar
• Chidrawar SM, Khan N, Chan YL, Nayak L, Moss PA. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun. Ageing3, 10 (2006).
   PubMedGoogle Scholar
• Mariani E, Sgobbi S, Meneghetti A et al. Perforins in human cytolytic cells: the effect of age. Mech. Ageing Dev.92(2–3), 195–209 (1996).
   PubMedGoogle Scholar
• Steele TA, Brahmi Z. Inhibition of human natural killer cell activity by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine is an early but post-binding event. J. Immunol.141(9), 3164–3169 (1988).
   PubMed Web of Science ®Google Scholar
• Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine18(16), 1613–1620 (2000).
   PubMed Web of Science ®Google Scholar
• Heron MP, Smith BL. Deaths: leading causes for 2003. Natl Vital Stat. Rep.55(10), 1–92 (2007).
   PubMedGoogle Scholar
• Hamilton BE, Minino AM, Martin JA et al. Annual summary of vital statistics: 2005. Pediatrics119(2), 345–360 (2007).
   PubMed Web of Science ®Google Scholar
• Bridges CB, Harper SA, Fukuda K et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.52(RR-8), 1–34 (2003).
   Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rivetti A et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet366(9492), 1165–1174 (2005).
   PubMed Web of Science ®Google Scholar
• Hak E, Nordin J, Wei F et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin. Infect. Dis.35(4), 370–377 (2002).
   PubMed Web of Science ®Google Scholar
• Bellei NC, Carraro E, Castelo A, Granato CF. Risk factors for poor immune response to influenza vaccination in elderly people. Braz. J. Infect. Dis.10(4), 269–273 (2006).
   PubMedGoogle Scholar
• Smith NM, Bresee JS, Shay DK et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-10), 1–42 (2006).
   PubMedGoogle Scholar
• Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA272(21), 1661–1665 (1994).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Intern. Med.158(16), 1769–1776 (1998).
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost–effectiveness in a health maintenance organization. Ann. Intern. Med.121(12), 947–952 (1994).
   PubMed Web of Science ®Google Scholar
• Bouree P. Immunity and immunization in elderly. Pathol. Biol. (Paris)51(10), 581–585 (2003).
   PubMedGoogle Scholar
• Shugarman LR, Hales C, Setodji CM, Bardenheier B, Lynn J. The influence of staff and resident immunization rates on influenza-like illness outbreaks in nursing homes. J. Am. Med. Dir. Assoc.7(9), 562–567 (2006).
   PubMedGoogle Scholar
• Almanzar G, Herndler-Brandstetter D, Chaparro SV et al. Immunodominant peptides from conserved influenza proteins – a tool for more efficient vaccination in the elderly? Wien. Med. Wochenschr.157(5–6), 116–121 (2007).
   PubMedGoogle Scholar
• Butcher SK, Lord JM. Stress responses and innate immunity: aging as a contributory factor. Aging Cell3(4), 151–160 (2004).
   PubMed Web of Science ®Google Scholar
• Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine13(15), 1445–1448 (1995).
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda A, Danenberg HD, Zakay-Rones Z, Gross DJ, Friedman G. The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly. Mech. Ageing Dev.102(2–3), 299–306 (1998).
   PubMed Web of Science ®Google Scholar
• Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Gross DJ, Friedman G. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. J. Clin. Endocrinol. Metab82(9), 2911–2914 (1997).
   PubMed Web of Science ®Google Scholar
• Evans TG, Judd ME, Dowell T et al. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine14(16), 1531–1537 (1996).
   PubMedGoogle Scholar
• Negrotto S, Malaver E, Alvarez ME et al. Aspirin and salicylate suppress polymorphonuclear apoptosis delay mediated by proinflammatory stimuli. J. Pharmacol. Exp. Ther.319(2), 972–979 (2006).
   PubMedGoogle Scholar
• Mazur I, Wurzer WJ, Ehrhardt C et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-κB-inhibiting activity. Cell Microbiol.9(7), 1683–1994 (2007).
   PubMedGoogle Scholar
• Pneumococcal and influenza vaccination levels among adults aged > or = 65 years – United States, 1995. MMWR Morb. Mortal. Wkly Rep.46(39), 913–919 (1997).
   PubMedGoogle Scholar
• Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA285(13), 1729–1735 (2001).
   PubMed Web of Science ®Google Scholar
• Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J. Infect. Dis.161(4), 728–735 (1990).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev. Med.23(5), 751–755 (1994).
   PubMedGoogle Scholar
• Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine9(6), 403–407 (1991).
   PubMedGoogle Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med.325(21), 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.46(RR-8), 1–24 (1997).
   PubMedGoogle Scholar
• Robbins JB, Schneerson R. Polysaccharide–protein conjugates: a new generation of vaccines. J. Infect. Dis.161(5), 821–832 (1990).
   PubMed Web of Science ®Google Scholar
• Baltimore RS. New challenges in the development of a conjugate pneumococcal vaccine. JAMA268(23), 3366–3367 (1992).
   PubMed Web of Science ®Google Scholar
• Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N. Engl. J. Med.309(23), 1434–1440 (1983).
   PubMed Web of Science ®Google Scholar
• Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N. Engl. J. Med.347(5), 340–346 (2002).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Law B et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol. Infect.127(2), 305–314 (2001).
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.56(RR-4), 1–40 (2007).
   PubMedGoogle Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch. Intern. Med.155(15), 1605–1609 (1995).
   PubMed Web of Science ®Google Scholar
• Kost RG, Straus SE. Postherpetic neuralgia – pathogenesis, treatment, and prevention. N. Engl. J. Med.335(1), 32–42 (1996).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain67(2–3), 241–251 (1996).
   PubMed Web of Science ®Google Scholar
• Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch. Intern. Med.157(11), 1209–1213 (1997).
   PubMed Web of Science ®Google Scholar
• Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology45(12 Suppl. 8), S41–S46 (1995).
   PubMed Web of Science ®Google Scholar
• Sederholm B, Peterson D. Zoster vaccine to prevent postherpetic neuralgia. J. Pain Palliat. Care Pharmacother.20(4), 41–42 (2006).
   PubMedGoogle Scholar
• Holcomb K, Weinberg JM. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia. J. Drugs Dermatol.5(9), 863–866 (2006).
   PubMedGoogle Scholar
• Robinson DM, Perry CM. Zoster vaccine live (Oka/Merck). Drugs Aging23(6), 525–531 (2006).
   PubMedGoogle Scholar
• Caple J. Varicella-zoster virus vaccine: a review of its use in the prevention of herpes zoster in older adults. Drugs Today (Barc.)42(4), 249–254 (2006).
   PubMedGoogle Scholar
• Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N. Engl. J. Med.356(13), 1338–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med.352(22), 2271–2284 (2005).
   PubMed Web of Science ®Google Scholar
• Irwin MR, Olmstead R, Oxman MN. Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of Tai Chi. J. Am. Geriatr. Soc.55(4), 511–517 (2007).
   PubMed Web of Science ®Google Scholar
• Smith TP, Kennedy SL, Fleshner M. Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men. J. Appl. Physiol97(2), 491–498 (2004).
   PubMed Web of Science ®Google Scholar
• Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-15), 1–48 (2006).
   PubMedGoogle Scholar
• Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep.55(RR-17), 1–37 (2006).
   PubMedGoogle Scholar
• Gergen PJ, McQuillan GM, Kiely M et al. A population-based serologic survey of immunity to tetanus in the United States. N. Engl. J. Med.332(12), 761–766 (1995).
   PubMed Web of Science ®Google Scholar
• Balestra DJ, Littenberg B. Should adult tetanus immunization be given as a single vaccination at age 65? A cost–effectiveness analysis. J. Gen. Intern. Med.8(8), 405–412 (1993).
   PubMedGoogle Scholar
• Bell BP, Kruszon-Moran D, Shapiro CN et al. Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine23(50), 5798–5806 (2005).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-7), 1–23 (2006).
   PubMedGoogle Scholar
• Genton B, D’Acremont V, Furrer HJ, Hatz C, Louis L. Hepatitis A vaccines and the elderly. Travel. Med. Infect. Dis.4(6), 303–312 (2006).
   PubMedGoogle Scholar
• Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv. Cancer Res.95, 115–145 (2006).
   PubMedGoogle Scholar
• Johansson J, Hellman L. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine. Vaccine25(9), 1676–1682 (2007).
   PubMed Web of Science ®Google Scholar
• Lavelle EC, O’Hagan DT. Delivery systems and adjuvants for oral vaccines. Expert. Opin. Drug Deliv.3(6), 747–762 (2006).
   PubMed Web of Science ®Google Scholar
• Pascual DM, Morales RD, Gil ED et al. Adjuvants: present regulatory challenges. Vaccine24(Suppl. 2), S2–S9 (2006).
   PubMedGoogle Scholar
• Ahluwalia N. Aging, nutrition and immune function. J. Nutr. Health Aging8(1), 2–6 (2004).
   PubMedGoogle Scholar
• Mahalanabis D, Basak M, Paul D et al. Antioxidant vitamins E and C as adjunct therapy of severe acute lower-respiratory infection in infants and young children: a randomized controlled trial. Eur. J. Clin. Nutr.60(5), 673–680 (2006).
   PubMedGoogle Scholar
• Ciocoiu M, Lupusoru EC, Colev V, Badescu M, Paduraru I. [The involvement of vitamins C and E in changing the immune response]. Rev. Med. Chir. Soc. Med. Nat. Iasi102(1–2), 93–96 (1998).
   PubMedGoogle Scholar
• Adolfsson O, Meydani SN. Nutrition and the aging immune response. Nestle Nutr. Workshop Ser. Clin. Perform. Programme6, 207–220 (2002).
   PubMedGoogle Scholar
• Saker KE. Nutrition and immune function. Vet. Clin. North Am. Small Anim. Pract.36(6), 1199–224, v (2006).
   PubMed Web of Science ®Google Scholar
• Kelley KW. The role of growth hormone in modulation of the immune response. Ann. NY Acad. Sci.594, 95–103 (1990).
   PubMed Web of Science ®Google Scholar
• Ribeiro F, Lopes RP, Nunes CP et al. Dehydroepiandrosterone sulphate enhances IgG and interferon-γ production during immunization to tuberculosis in young but not aged mice. Biogerontology8(2), 209–220 (2007).
   PubMed Web of Science ®Google Scholar
• Pagani S, Meazza C, Travaglino P, Moretta A, Bozzola M. Effect of growth hormone therapy on the proinflammatory cytokine profile in growth hormone-deficient children. Eur. Cytokine Netw.16(1), 65–69 (2005).
   PubMedGoogle Scholar
• Toogood AA. The somatopause: an indication for growth hormone therapy? Treat. Endocrinol.3(4), 201–209 (2004).
   PubMedGoogle Scholar
• Tentori L, Graziani G. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? Pharmacol. Res.55(5), 359–369 (2007).
   PubMed Web of Science ®Google Scholar
• Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science314(5800), 781–784 (2006).
   PubMed Web of Science ®Google Scholar
• Levites Y, Smithson LA, Price RW et al. Insights into the mechanisms of action of anti-Aβ antibodies in Alzheimer’s disease mouse models. FASEB J.20(14), 2576–2578 (2006).
   PubMed Web of Science ®Google Scholar
• Nikolic WV, Bai Y, Obregon D et al. Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl Acad. Sci. USA104(7), 2507–2512 (2007).
   PubMed Web of Science ®Google Scholar
• Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J. Immunol.176(8), 4608–4615 (2006).
   PubMed Web of Science ®Google Scholar
• Li A, Ojogho O, Franco E et al. Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces Foxp3+ regulatory T cells in vitro. Vaccine24(23), 5036–5046 (2006).
   PubMed Web of Science ®Google Scholar
• Rapoport AP. Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come. Bone Marrow Transplant.37(3), 239–247 (2006).
   PubMedGoogle Scholar